Loading company…
Osanni Bio discovers and develops therapeutic medicines, with a focus on ophthalmology and cardiology.
Osanni Bio advances therapeutic programs through proof-of-concept development, with programs intended for transfer to affiliated companies called Avians. Founded in 2022 by CEO Michael Ackermann, Ph.D., it is based in San Francisco, US. It raised USD 190.00 mn in Series B funding led by Patient Square Capital, with Horowitz Group, Invus Financial Advisors and Retinal Degeneration Fund also investing.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in